Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Ratain

Showing results (31-40 of 366) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controlsFederico Innocenti, Mark J Ratain
Cancer Chemotherapy and Pharmacology|April 1, 2022
Lurbinectedin-induced thrombocytopenia: the role of body surface areaApostolos Papachristos, Mark J Ratain
JAMA Oncology|October 14, 2016
Drug-Drug Interactions With Oral Antineoplastic AgentsSandeep Parsad, Mark J Ratain
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan treatment in cancer patients with UGT1A1 polymorphismsFederico Innocenti, Mark J Ratain
Nature Biotechnology|November 10, 2023
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?Austin Wesevich, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2010
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology productsSoonmo Peter Kang, Mark J Ratain
BMJ (Clinical Research Ed.)|February 27, 2007
Prescribing oral chemotherapySandeep D Parsad, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Testing the wrong hypothesis in phase II oncology trials: there is a better alternativeMark J Ratain, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-LetterDaniel A Goldstein, Mark J Ratain
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Introduction by the Guest EditorsMark J Ratain, Allen S Lichter
Pageof 37

Showing results (31-40 of 366) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controlsFederico Innocenti, Mark J Ratain
Cancer Chemotherapy and Pharmacology|April 1, 2022
Lurbinectedin-induced thrombocytopenia: the role of body surface areaApostolos Papachristos, Mark J Ratain
JAMA Oncology|October 14, 2016
Drug-Drug Interactions With Oral Antineoplastic AgentsSandeep Parsad, Mark J Ratain
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan treatment in cancer patients with UGT1A1 polymorphismsFederico Innocenti, Mark J Ratain
Nature Biotechnology|November 10, 2023
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?Austin Wesevich, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2010
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology productsSoonmo Peter Kang, Mark J Ratain
BMJ (Clinical Research Ed.)|February 27, 2007
Prescribing oral chemotherapySandeep D Parsad, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Testing the wrong hypothesis in phase II oncology trials: there is a better alternativeMark J Ratain, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-LetterDaniel A Goldstein, Mark J Ratain
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Introduction by the Guest EditorsMark J Ratain, Allen S Lichter
Pageof 37